Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Sommerer

Showing results (41-50 of 155) with videos related to

Pageof 16
Sort By:
Trials|December 16, 2014
The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trialClaudia Sommerer, Matthias Schaier, Christian Morath, et al.
Expert Opinion on Pharmacotherapy|May 3, 2017
An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockadeFlorian Kälble, Matthias Schaier, Sebastian Schäfer, et al.
Transplantation|November 30, 2006
Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignanciesClaudia Sommerer, Mathias Konstandin, Thomas Dengler, et al.
Therapeutic Drug Monitoring|August 30, 2012
Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adultsHeiko Billing, Claudia Sommerer, Thomas Giese, et al.
Annals of Transplantation|January 25, 2014
Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective studyNiels Steinebrunner, Catharina Sandig, Claudia Sommerer, et al.
Therapeutic Drug Monitoring|September 30, 2015
Analytical Aspects of the Implementation of Biomarkers in Clinical TransplantationMaria Shipkova, Olga Millán López, Nicolas Picard, et al.
Nephron|September 10, 2002
Cyclosporin A toxicity of the renal allograft--a late complication and potentially reversibleClaudia Sommerer, Okaf Hergesell, Anna-Maria Nahm, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 7, 2013
Assessment of renal allograft fibrosis by transient elastographyClaudia Sommerer, Michael Scharf, Christoph Seitz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 26, 2015
High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitisMatthias Schaier, Christian Scholl, Dominik Scharpf, et al.
Trials|February 19, 2016
Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trialClaudia Sommerer, Barbara Suwelack, Duska Dragun, et al.
Pageof 16

Showing results (41-50 of 155) with videos related to

Sort By:
Pageof 16
Trials|December 16, 2014
The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trialClaudia Sommerer, Matthias Schaier, Christian Morath, et al.
Expert Opinion on Pharmacotherapy|May 3, 2017
An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockadeFlorian Kälble, Matthias Schaier, Sebastian Schäfer, et al.
Transplantation|November 30, 2006
Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignanciesClaudia Sommerer, Mathias Konstandin, Thomas Dengler, et al.
Therapeutic Drug Monitoring|August 30, 2012
Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adultsHeiko Billing, Claudia Sommerer, Thomas Giese, et al.
Annals of Transplantation|January 25, 2014
Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective studyNiels Steinebrunner, Catharina Sandig, Claudia Sommerer, et al.
Therapeutic Drug Monitoring|September 30, 2015
Analytical Aspects of the Implementation of Biomarkers in Clinical TransplantationMaria Shipkova, Olga Millán López, Nicolas Picard, et al.
Nephron|September 10, 2002
Cyclosporin A toxicity of the renal allograft--a late complication and potentially reversibleClaudia Sommerer, Okaf Hergesell, Anna-Maria Nahm, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 7, 2013
Assessment of renal allograft fibrosis by transient elastographyClaudia Sommerer, Michael Scharf, Christoph Seitz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 26, 2015
High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitisMatthias Schaier, Christian Scholl, Dominik Scharpf, et al.
Trials|February 19, 2016
Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trialClaudia Sommerer, Barbara Suwelack, Duska Dragun, et al.
Pageof 16